Biogen Inc. Share Price and Company Fundamentals
Last traded: Last Wednesday at 8:00 PM
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Key Metrics
PE ratio
14.20
PB ratio
3.86
Dividend yield
Beta
0.44
Market cap
$41.26B
Enterprise value
$46.54B
Company profile
| Industry / Sector | Drug Manufacturers—General / Healthcare |
|---|---|
| Full time employees | 9100 |
| Website | http://www.biogen.com |
| Mailing address | 225 Binney Street Cambridge MA 02142 United States |
| Phone / Fax | 617 679 2000 / |
Dividends
Biogen Inc. does not pay dividends.
Company Executives
As of May 2021, following are the company executives and directors listed on Biogen Inc..
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Michel Vounatsos | CEO & Director | 58 | 4.51M |
| Mr. Michael R. McDonnell | Exec. VP & CFO | 56 | 1.56M |
| Ms. Susan H. Alexander | Exec. VP, Chief Legal Officer & Sec. | 63 | 1.58M |
| Dr. Alfred W. Sandrock Jr. | Exec. VP of R&D | 62 | 1.76M |
| Mr. Chirfi Guindo | Exec. VP of Global Product Strategy & Commercialization | 54 | 1.17M |
| Ms. Robin C. Kramer | Sr. VP & Chief Accounting Officer | 54 | |
| Mr. Michael Hencke | Director of Investor Relations | ||
| Ms. Natacha Gassenbach | Chief Communication Officer & Head of Corp. Affairs | ||
| Dr. Ginger Gregory | Exec. VP & Chief HR Officer | 52 | |
| Dr. Alphonse Galdes | Exec. VP of Pharmaceutical Operations & Technology | 67 |
Profitability and management effectiveness
Profit margin
23.89%
Operating margin
29.40%
Return on assets
9.27%
Return on equity
26.49%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Biogen Inc. is 41.26B and its enterprise value is 46.54B. The enterprise value to revenue ratio of BIIB is 3.69.
The BIIB's stocks Beta value is 0.44 making it 56% less volatile compared to NASDAQ market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Biogen Inc. (NASDAQ:BIIB) Frequently Asked Questions
1. What is Biogen Inc.'s Stock Symbol?
Biogen Inc. trades on NASDAQ under the ticker symbol "BIIB".
2. What is Biogen Inc.'s stock price today?
One share of BIIB stock can currently be purchased for approximately $274.02.
3. How can I contact Biogen Inc.?
Biogen Inc.'s mailing address is 225 Binney Street Cambridge MA 02142 United States. The company can be reached via phone at 617 679 2000.
4. What is Biogen Inc.'s official website?
The official website of Biogen Inc. is http://www.biogen.com.